^
Association details:
| Biomarker: | ROS1 mutation |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
877P - ROS1 mutations as potential negative predictor for response of immunotherapy in patient with head and neck cancer
Published date:
10/16/2023
Excerpt:
Immune cell analysis showed that Regulatory Tregs T-cells were significantly less abundant in the ROS1-Mut group (P=0.037), indicating an deactivated antitumor immune microenvironment….We identified that ROS1 mutation predicted the resistance to ICIs in HNSCs. The clinical delivery of ICIs should be cautious in those patients.
